GUNN & Co INVESTMENT MANAGEMENT INC. Has $740,000 Position in Eli Lilly and Company (NYSE:LLY)

GUNN & Co INVESTMENT MANAGEMENT INC. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 45.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 835 shares of the company’s stock after selling 699 shares during the quarter. GUNN & Co INVESTMENT MANAGEMENT INC.’s holdings in Eli Lilly and Company were worth $740,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Lynx Investment Advisory acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Morton Brown Family Wealth LLC boosted its position in shares of Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC raised its position in Eli Lilly and Company by 53.3% in the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after buying an additional 16 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $891.66 on Friday. The company has a market capitalization of $847.44 billion, a price-to-earnings ratio of 131.32, a PEG ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock’s 50 day moving average is $921.12 and its 200-day moving average is $860.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LLY shares. Barclays raised their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Guggenheim upped their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,002.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.